monokey
2022-02-11
Great ariticle, would you like to share it?
@李秋实医药投资:
今天大家很关心美国FDA对中国某企业的新药审批情况,我认为,其实即使拿了竞争激烈的拥挤靶点出海获配了也意义不大,在欧美市场三名开外获批的药物,除非有巨大的数据优异,一般也卖不上什么量,比如某药企的BTK,这几个PD–1的企业就更是了。 创新药2.0的药企,是能够做出全球进度top2的,first in class或者真的best in class的药企,最近我们在一级市场也经常看到这样的企业,一些有战略格局的上市公司创新药企业目前也在布局这样的新靶点、新机理的硬核创新药,这才是中国创新药企出海的最佳路径,当然,研发也会更难,更大的风险,也会有更大的,更长久的回报。 相信中国创新药企,下一回,咱们拿点硬货出海。。
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP,发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":631826164,"tweetId":"631826164","gmtCreate":1644589118931,"gmtModify":1644589118931,"author":{"id":3581626101307210,"idStr":"3581626101307210","authorId":3581626101307210,"authorIdStr":"3581626101307210","name":"monokey","avatar":"https://static.tigerbbs.com/514ee6a47d84758c4210358fba517b36","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>\nGreat ariticle, would you like to share it?</body></html>","htmlText":"<html><head></head><body>\nGreat ariticle, would you like to share it?</body></html>","text":"Great ariticle, would you like to share it?","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/631826164","repostId":631183754,"repostType":1,"repost":{"magic":2,"id":631183754,"tweetId":"631183754","gmtCreate":1644542466974,"gmtModify":1644602967464,"author":{"id":4097915146279240,"idStr":"4097915146279240","authorId":4097915146279240,"authorIdStr":"4097915146279240","name":"李秋实医药投资","avatar":"https://static.tigerbbs.com/1103cc0c6a5fac44564371c1fa44d376","vip":2,"userType":2,"introduction":"熙德博远资本创始合伙人","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1265,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>\n今天大家很关心美国FDA对中国某企业的新药审批情况,我认为,其实即使拿了竞争激烈的拥挤靶点出海获配了也意义不大,在欧美市场三名开外获批的药物,除非有巨大的数据优异,一般也卖不上什么量,比如某药企的BTK,这几个PD–1的企业就更是了。<br><br>创新药2.0的药企,是能够做出全球进度top2的,first in class或者真的best in class的药企,最近我们在一级市场也经常看到这样的企业,一些有战略格局的上市公司创新药企业目前也在布局这样的新靶点、新机理的硬核创新药,这才是中国创新药企出海的最佳路径,当然,研发也会更难,更大的风险,也会有更大的,更长久的回报。<br><br>相信中国创新药企,下一回,咱们拿点硬货出海。。<br></body></html>","htmlText":"<html><head></head><body>\n今天大家很关心美国FDA对中国某企业的新药审批情况,我认为,其实即使拿了竞争激烈的拥挤靶点出海获配了也意义不大,在欧美市场三名开外获批的药物,除非有巨大的数据优异,一般也卖不上什么量,比如某药企的BTK,这几个PD–1的企业就更是了。<br><br>创新药2.0的药企,是能够做出全球进度top2的,first in class或者真的best in class的药企,最近我们在一级市场也经常看到这样的企业,一些有战略格局的上市公司创新药企业目前也在布局这样的新靶点、新机理的硬核创新药,这才是中国创新药企出海的最佳路径,当然,研发也会更难,更大的风险,也会有更大的,更长久的回报。<br><br>相信中国创新药企,下一回,咱们拿点硬货出海。。<br></body></html>","text":"今天大家很关心美国FDA对中国某企业的新药审批情况,我认为,其实即使拿了竞争激烈的拥挤靶点出海获配了也意义不大,在欧美市场三名开外获批的药物,除非有巨大的数据优异,一般也卖不上什么量,比如某药企的BTK,这几个PD–1的企业就更是了。 创新药2.0的药企,是能够做出全球进度top2的,first in class或者真的best in class的药企,最近我们在一级市场也经常看到这样的企业,一些有战略格局的上市公司创新药企业目前也在布局这样的新靶点、新机理的硬核创新药,这才是中国创新药企出海的最佳路径,当然,研发也会更难,更大的风险,也会有更大的,更长久的回报。 相信中国创新药企,下一回,咱们拿点硬货出海。。","highlighted":2,"essential":2,"paper":1,"link":"https://laohu8.com/post/631183754","repostId":0,"isVote":1,"tweetType":1,"commentLimit":10,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":542,"xxTargetLangEnum":"ZH_CN"},"isVote":1,"tweetType":1,"viewCount":527,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":36,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/631826164"}
精彩评论